Figure 9.

LX2343 repressed JNK/APP^Thr668-mediated Aβ generation and protected synaptic integrity in APP/PS1 transgenic mice. Western blotting and its quantification results demonstrated that LX2343 reduced the phosphorylation of JNK and APP^Thr668, decreased the protein level of sAPPβ, and had no effects on the protein level of BACE1 in cortical homogenates of APP/PS1 transgenic mice (A, B) (t test, n=4. ^*P<0.05, ^**P<0.01 vs TV). ELISA results demonstrated that LX2343 decreased the sAPPβ in cortex and hippocampus homogenates of APP/PS1 transgenic mice (C) (t test, n=10. ^*P<0.05, ^**P<0.01 vs TV). Western blotting and its quantification results demonstrated that LX2343 increased the protein levels of synaptophysin, PSD95 and VAMP2 in cortex homogenates of APP/PS1 transgenic mice (D, E) (t test, n=4. ^*P<0.05, ^**P<0.01 vs TV). GAPDH was used as loading control in Western blot assays. NV: nontransgenic mice administered with vehicle; TV: Transgenic mice administered with vehicle; LX2343: transgenic mice administered with 10 mg·kg⁻¹·d⁻¹ LX2343. Values are mean±SEM.